Navigation Links
Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
Date:9/24/2008

ed to display substantial antiviral activity based on preclinical results. Additionally, absorption was enhanced when ANA598 was taken with food, indicating that it should not be necessary to take ANA598 on an empty stomach in order to achieve desired plasma drug levels.

Additional detail from the Phase I study, including full PK results from the twice-daily 800 mg cohort, will be presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), to be held in San Francisco, California, October 31 - November 4, 2008. Abstracts can be viewed at the AASLD website at http://www.aasld.org.

ANA598 Program Update

Anadys is now finalizing preparations to begin a Phase Ib trial of ANA598 in HCV patients early in the fourth quarter. The study will be conducted at several sites in the United States. The regulatory review necessary to initiate the study has been completed. In the Phase Ib monotherapy study, naive genotype 1 patients will receive ANA598 over three days, at doses of 200 mg bid, 400 mg bid or 800 mg bid. Ten patients are planned to be enrolled in each of the three cohorts, eight on active treatment and two on placebo. Anadys expects to have viral load data from all three cohorts in the first quarter of 2009. Anadys may elect to explore other dose levels of ANA598 and/or once-daily dosing in this study, depending on data from the first three cohorts.

In September, Anadys initiated long-term chronic toxicology studies of ANA598. As communicated in April of this year, Anadys made the strategic decision to accelerate into 2008 certain non-clinical activities for the ANA598 program, including the initiation of these long-term toxicology studies and the manufacture of additional drug substance. If ANA598 is successful in early stage clinical trials, it is anticipated that the acceleration of these non-clinical activities into 2008 will enable a more rapid
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
2. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
7. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
8. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
9. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
10. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
11. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... NOTTINGHAM, England , Oct. 1, 2014 ... today announced that its subsidiary, Molecular Profiles Ltd., is ... at the annual CPhI/ICSE Worldwide event in ... companies with the rapid development of both standard and ... screening platform, which incorporates the company,s existing formulation and ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it ... Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder and ... proud that our quality of service has been recognized ... lifesaving support and continuity of care to patients of ... the United States ." NeuroCall ...
(Date:10/1/2014)... DIEGO , Oct. 1, 2014   Cypher ... the appointment of J. Patrick Ravenel as ... of enterprise software and systems experience and a proven ... 500 companies. "Patrick has been recognized ... software and systems and is known industry-wide for delivering ...
Breaking Medicine Technology:Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3NeuroCall Awarded Joint Commission Accreditation 2Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2
... DIEGO, Dec. 5 Orexigen(R) Therapeutics, Inc.,(Nasdaq: ... resources,focus its efforts on its late-stage obesity programs and ... The key aspects of these changes are as ... The exploratory proof-of-concept Phase 2 trials for OREX-003,(zonisamide ...
... Kiadis,Pharma announces today that it has successfully completed ... I/II clinical trial. ATIR(TM), a donor,lymphocyte cell based ... Host Disease (GvHD) and allow early immune reconstitution ... blood cancer,patients were treated with no cases of ...
Cached Medicine Technology:Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 2Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 3Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations 2
(Date:10/1/2014)... adage that encourages people to keep their "eyes on ... to exercise. When walking, staying focused on a specific ... shorter and help people walk there faster, psychology researchers ... walking while looking around the environment naturally, offers a ... "People are less interested in exercise if physical activity ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Insuranceragents.info ... find a good life insurance plan for vulnerable family ... for vulnerable family members. Providers in the family should ... will cause financial hardships for the rest of the ... of policies. Families can benefit more from temporary coverage ...
(Date:10/1/2014)... 2014 First Warning Systems, a pioneer ... changes throughout the body, announced the company is changing ... the company’s breadth of upcoming product releases. The initial ... technology. , “Our initial focus will be an ‘Internet ... abnormal circadian cellular changes over time,” said Rob Royea, ...
(Date:10/1/2014)... October 01, 2014 Farmington Company ... a redefined mission and visual identity helping brokers, ... partnering with them to create greater benefit communication ... that focuses on empowering customers to better leverage ... The crown jewel of the rebrand is the ...
(Date:10/1/2014)... October 01, 2014 Beverly Hills licensed ... Mojas is celebrating 20 years of private practice in ... of people to achieve greater joy and fulfillment in ... of warning signs and suggestions for anyone who suspects ... explains: “Believe it or not, it’s not always ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3
... an interesting,snapshot of Minnesotans, changing driving habits, retail ... percent decline compared to sales in July 2007.,According ... motorists,bought 211,982,582 gallons of gasoline in July, compared ... the amount of ethanol-based,E85 sold during the same ...
... medical student in the country. That,s because the three-part ... delivered in a new way: by listening to a ... an Achilles heel in the medical field. , ... test know they don,t have this auditory skill," says Michael ...
... Trevino, master permanent make-up artist and educator joins Nouveau Cosmetique ... advance the education of permanent cosmetic professionals in the US. ... ... August 25, 2008 -- Nouveau Cosmetique USA, Inc., the exclusive ...
... (PTCB) Exhibits at this week,s National Association of Chain Drug ... solutions for enhanced patient safety and the benefits of pharmacy ... ... CA (PRWEB) August 25, 2008 - The https://www.ptcb.org/ ...
... HMS Holdings Corp. (Nasdaq:,HMSY) today announced that it ... which will be held September 3-5, 2008 at the,Four ... and Chief Financial Officer of HMS Holdings Corp.,will present ... A live broadcast of the Company,s presentation can ...
... 96 on the, 2008 Inc. 500, with three-year sales growth ... ... Inc. magazine today ranked The,Coding Source No. 96 on its 27th ... list is the most,comprehensive look at the most important segment of the ...
Cached Medicine News:Health News:Listen up! 2Health News:Master Permanent Make-up Artist and Educator Sulema Trevino Joins Nouveau Cosmetique Team 2Health News:Pharmacy Technician Certification Board (PTCB) Exhibits at 2008 NACDS Pharmacy & Technology Conference 2Health News:Pharmacy Technician Certification Board (PTCB) Exhibits at 2008 NACDS Pharmacy & Technology Conference 3Health News:The Coding Source Named to Inc. Magazine's 27th Annual List of America's 500 Fastest-Growing Private Companies 2Health News:The Coding Source Named to Inc. Magazine's 27th Annual List of America's 500 Fastest-Growing Private Companies 3
... Bringing together the best of both ... intraocular instrument is the latest addition ... lightweight Eraser bipolar cautery instruments for ... hemostasis with extrusion aspiration and backflush ...
...
...
...
Medicine Products: